Low Financial LeverageZero reported debt materially lowers refinancing and interest-rate risks over the medium term, preserving flexibility for R&D financing choices. For an early-stage biotech, low leverage improves chances to structure grants, equity or milestone financings without immediate debt-service pressure, aiding durability.

Proprietary Target Platform (α10β1)A focused, proprietary biological target provides a durable competitive advantage: it creates a clear R&D platform spanning orthopedics and oncology, supports IP build-out, and can enable multiple product/diagnostic opportunities and strategic partnerships that persist beyond short-term cycles.

Gross Profitability On Core ProductsRecording positive gross profit indicates the core product economics may be viable once fixed R&D and G&A are scaled or optimized. This suggests potential for sustainable unit-level margins on commercialization, making future profitability achievable if revenue scales and overhead is controlled.

Bears Say

Persistent Operating Cash BurnSustained large negative operating cash flows create structural funding dependence, forcing repeated external raises that dilute shareholders and divert management focus. Without a durable path to positive cash flow or secured long-term funding, R&D timelines and trials risk delay or scale-back over months.

Negative Shareholders' EquityNegative equity materially weakens balance-sheet resilience and can impair the company’s ability to access favourable financing or enter partnerships. It increases counterparty and investor caution, possibly raising cost of capital and constraining strategic options over the medium term absent recapitalization.

Loss-Making With Revenue VolatilityPersistent operating and net losses combined with volatile and declining revenue signal weak commercialization traction and execution risk. Structural profitability remains distant, making long-term sustainability contingent on either durable revenue growth or significant cost restructuring and successful clinical/commercial milestones.

Xintela AB News

1XT Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Xintela AB (1XT) is scheduled to report 4th quarter earnings on 02/27/2026. Regarding Q4 estimates, Wall Street analysts...

8d ago

1XT Upcoming Earnings Report: What to Expect?

Xintela AB (1XT) is scheduled to report 2nd quarter earnings on 08/29/2025. Regarding Q2 estimates, Wall Street analysts...

6M ago

XINT FAQ

What was Xintela AB’s price range in the past 12 months?

Xintela AB lowest stock price was kr0.24 and its highest was kr0.70 in the past 12 months.

What is Xintela AB’s market cap?

Xintela AB’s market cap is kr218.76M.

When is Xintela AB’s upcoming earnings report date?

Xintela AB’s upcoming earnings report date is May 22, 2026 which is in 78 days.

How were Xintela AB’s earnings last quarter?

Xintela AB released its earnings results on Feb 27, 2026. The company reported -kr0.02 earnings per share for the quarter, missing the consensus estimate of -kr0.01 by -kr0.01.

Is Xintela AB overvalued?

According to Wall Street analysts Xintela AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xintela AB pay dividends?

Xintela AB does not currently pay dividends.

What is Xintela AB’s EPS estimate?

Xintela AB’s EPS estimate is -0.01.

How many shares outstanding does Xintela AB have?

Xintela AB has 861,266,850 shares outstanding.

What happened to Xintela AB’s price movement after its last earnings report?

Xintela AB reported an EPS of -kr0.02 in its last earnings report, missing expectations of -kr0.01. Following the earnings report the stock price went up 1.838%.

Which hedge fund is a major shareholder of Xintela AB?

Currently, no hedge funds are holding shares in SE:XINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Xintela AB

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.